Company intelligence / Profile preview

Sirana Pharma

München, Bayern, Germany

Ownership: Private
Development stage: Preclinical

Overview

Sirana Pharma is developing innovative therapies for musculoskeletal disorders using a proprietary microRNA-targeting platform. The company has entered into a collaborative research agreement with Pfizer to investigate treatments for rare bone diseases. Its approach aims at substantial regenerative recovery of diseased muscle and bone tissue. Clinical results have not been disclosed publicly as of the latest available information.

Therapeutic areas: Rare DiseasesRheumatology
Modalities: microRNA (miRNA)-targeting therapeutics
Industry: Biotech

Drug pipeline

3 assets

SRN-21

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Pfizer Inc. (collaborative research agreement on rare bone disease)

Beyond the preview

Go deeper on Sirana Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sirana Pharma.

Explore the full profile